Clinical Trial Update: Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab with apatinib, carboplatin, and etoposide in extensive-stage small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• CARBOPLATIN (Carboplatin)
• Camrelizumab (camrelizumab)
• Etoposide (Etoposide)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Small-cell Lung Cancer | Phase 2 | Status: UNKNOWN